Abstract
Stimulation of the bradykinin (BK) B2 receptor by kinins is associated with pathophysiological as well as pronounced beneficial effects. Consequently, interference with BK B2 receptors by either antagonism or agonism offers promising therapeutic approaches for the development of drugs for the treatment of various human diseases. BK B2 receptor antagonists may prove useful for the treatment of pathological situations caused by excessively increased local kinin concentrations, such as inflammation, tissue injury and pain. Beneficial effects of peptide BK B2 receptor antagonists in perennial rhinitis, asthma and brain edema have already been demonstrated in clinical trials. On the other hand, kinins have also been identified as potent vasodilatory and organ-protective peptides. Therefore, BK B2 receptor agonists may have the potential to become valuable therapeutics in the treatment of cardiovascular diseases such as hypertension, myocardial hypertrophy, myocardial infarction and arrhythmias as well as diabetic disorders. For both approaches, potent, selective and even orally active non-peptide compounds have been discovered recently.
Keywords: kallikrein-kinin system, receptor antagonism, bradyzide
Current Medicinal Chemistry
Title: Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor
Volume: 9 Issue: 9
Author(s): H. Heitsch
Affiliation:
Keywords: kallikrein-kinin system, receptor antagonism, bradyzide
Abstract: Stimulation of the bradykinin (BK) B2 receptor by kinins is associated with pathophysiological as well as pronounced beneficial effects. Consequently, interference with BK B2 receptors by either antagonism or agonism offers promising therapeutic approaches for the development of drugs for the treatment of various human diseases. BK B2 receptor antagonists may prove useful for the treatment of pathological situations caused by excessively increased local kinin concentrations, such as inflammation, tissue injury and pain. Beneficial effects of peptide BK B2 receptor antagonists in perennial rhinitis, asthma and brain edema have already been demonstrated in clinical trials. On the other hand, kinins have also been identified as potent vasodilatory and organ-protective peptides. Therefore, BK B2 receptor agonists may have the potential to become valuable therapeutics in the treatment of cardiovascular diseases such as hypertension, myocardial hypertrophy, myocardial infarction and arrhythmias as well as diabetic disorders. For both approaches, potent, selective and even orally active non-peptide compounds have been discovered recently.
Export Options
About this article
Cite this article as:
Heitsch H., Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor, Current Medicinal Chemistry 2002; 9 (9) . https://dx.doi.org/10.2174/0929867024606722
DOI https://dx.doi.org/10.2174/0929867024606722 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry New Therapeutic Strategies in Perinatal Stroke
Current Drug Targets - CNS & Neurological Disorders Use of Telemetry Blood Pressure Transmitters to Measure Intracranial Pressure (ICP) in Freely Moving Rats
Current Neurovascular Research Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Progressive Brain Damage and Alterations in Dendritic Arborization after Collagenase-Induced Intracerebral Hemorrhage in Rats
Current Neurovascular Research Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Structural Modifications of Matrine-Type Alkaloids
Mini-Reviews in Medicinal Chemistry The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Peptide Aptamers: Development and Applications
Current Topics in Medicinal Chemistry Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Topical Delivery of Antioxidants
Current Drug Delivery Development of FXR, PXR and CAR Agonists and Antagonists for Treatment of Liver Disorders
Current Topics in Medicinal Chemistry Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Modulation of the Peripheral and Central Inflammatory Responses by a-Melanocyte Stimulating Hormone
Current Protein & Peptide Science A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety